Sponsored by GSK
Dec 2022
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.
Sponsored by Biogen
Jun 2021
A one-hour educational webinar on the implications of matched adjusted indirect treatment comparisons in rare disease, using SMA as an example. Webinar will provide both statistical and clinical perspective.
Sponsored by Biogen
Feb 2021
This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.
Dec 2020
This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.
Nov 2020
This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.
Oct 2020
This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.